Personalized Peptide Vaccine Shows Promise Against Advanced Lung Cancer
A personalized dendritic cell vaccine using tumor-specific neoantigen peptides achieved a 25% response rate and 75% disease control rate in heavily pretreated advanced lung cancer patients with only mild side effects.
Quick Facts
What This Study Found
In 12 advanced lung cancer patients, personalized neoantigen DC vaccine achieved 25% objective response rate, 75% disease control rate, 5.5-month median progression-free survival, and 7.9-month median overall survival with only grade 1-2 adverse events.
Key Numbers
12 patients; 85 vaccine treatments; median 5 doses/person; 12-30 neoantigens/patient; ORR 25%; DCR 75%; mPFS 5.5 months; mOS 7.9 months; all AEs grade 1-2
How They Did This
Single-arm, 2-center pilot study. Whole-exome and RNA sequencing of tumor biopsies identified candidate neoantigens. 12-30 neoantigen peptides per patient were used to pulse autologous dendritic cells. 85 total vaccine treatments administered (median 5 doses/person, range 3-14).
Why This Research Matters
Lung cancer is the deadliest cancer worldwide, and many patients exhaust standard treatment options. Personalized neoantigen vaccines represent a fundamentally different approach that trains the immune system to specifically target each patient's unique tumor.
The Bigger Picture
Neoantigen vaccines are a frontier of personalized cancer immunotherapy. This pilot study adds to growing evidence that peptide-based vaccines can benefit even heavily pretreated cancer patients, potentially complementing checkpoint inhibitors and other immunotherapies.
What This Study Doesn't Tell Us
Very small sample size (12 patients). Single-arm design without a control group. All patients were heavily pretreated, making it difficult to compare outcomes. Neoantigen identification and vaccine production are complex and time-consuming. Requires fresh tumor biopsy material.
Questions This Raises
- ?Would combining neoantigen vaccines with checkpoint inhibitors improve response rates?
- ?Can the vaccine manufacturing process be streamlined for broader clinical use?
- ?Would earlier use of neoantigen vaccines (before heavy pretreatment) produce better outcomes?
Trust & Context
- Key Stat:
- 75% disease control Three-quarters of heavily pretreated advanced lung cancer patients achieved disease control with personalized neoantigen DC vaccine
- Evidence Grade:
- Low-to-moderate evidence: pilot study with only 12 patients and no control group, but uses rigorous genomic-guided personalization and demonstrates a clear clinical signal.
- Study Age:
- Published in 2021. Neoantigen vaccine research has accelerated significantly with multiple larger clinical trials now underway.
- Original Title:
- Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.
- Published In:
- Signal transduction and targeted therapy, 6(1), 26 (2021)
- Authors:
- Ding, Zhenyu(2), Li, Qing(2), Zhang, Rui(5), Xie, Li, Shu, Yang, Gao, Song, Wang, Peipei, Su, Xiaoqing, Qin, Yun, Wang, Yuelan, Fang, Juemin, Zhu, Zhongzheng, Xia, Xuyang, Wei, Guochao, Wang, Hui, Qian, Hong, Guo, Xianling, Gao, Zhibo, Wang, Yu, Wei, Yuquan, Xu, Qing, Xu, Heng, Yang, Li
- Database ID:
- RPEP-05348
Evidence Hierarchy
Frequently Asked Questions
What is a neoantigen vaccine?
A neoantigen vaccine is made by identifying unique mutations in a patient's tumor, creating synthetic peptides that match those mutations, and using them to train the patient's immune cells to recognize and attack the cancer. Each vaccine is completely personalized.
Is this treatment available to lung cancer patients now?
Not as standard care. Neoantigen vaccines are currently available only through clinical trials. The process requires tumor sequencing, bioinformatics analysis, and custom peptide manufacturing, which is complex and time-intensive.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05348APA
Ding, Zhenyu; Li, Qing; Zhang, Rui; Xie, Li; Shu, Yang; Gao, Song; Wang, Peipei; Su, Xiaoqing; Qin, Yun; Wang, Yuelan; Fang, Juemin; Zhu, Zhongzheng; Xia, Xuyang; Wei, Guochao; Wang, Hui; Qian, Hong; Guo, Xianling; Gao, Zhibo; Wang, Yu; Wei, Yuquan; Xu, Qing; Xu, Heng; Yang, Li. (2021). Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.. Signal transduction and targeted therapy, 6(1), 26. https://doi.org/10.1038/s41392-020-00448-5
MLA
Ding, Zhenyu, et al. "Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.." Signal transduction and targeted therapy, 2021. https://doi.org/10.1038/s41392-020-00448-5
RethinkPeptides
RethinkPeptides Research Database. "Personalized neoantigen pulsed dendritic cell vaccine for ad..." RPEP-05348. Retrieved from https://rethinkpeptides.com/research/ding-2021-personalized-neoantigen-pulsed-dendritic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.